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Abstract Secondary bacterial infections (SBIs) exacerbate
influenza-associated disease and mortality. Antimicrobial
agents can reduce the severity of SBIs, but many have
limited efficacy or cause adverse effects. Thus, new treat-
ment strategies are needed. Kinetic models describing the
infection process can help determine optimal therapeutic
targets, the time scale on which a drug will be most
effective, and how infection dynamics will change under
therapy. To understand how different therapies perturb the
dynamics of influenza infection and bacterial coinfection
and to quantify the benefit of increasing a drug’s efficacy or
targeting a different infection process, I analyzed data from
mice treated with an antiviral, an antibiotic, or an immune
modulatory agent with kinetic models. The results suggest
that antivirals targeting the viral life cycle are most effi-
cacious in the first 2 days of infection, potentially because
of an improved immune response, and that increasing the
clearance of infected cells is important for treatment later
in the infection. For a coinfection, immunotherapy could
control low bacterial loads with as little as 20 % efficacy,
but more effective drugs would be necessary for high
bacterial loads. Antibiotics targeting bacterial replication
and administered 10 h after infection would require 100 %
efficacy, which could be reduced to 40 % with prophylaxis.
Combining immunotherapy with antibiotics could sub-
stantially increase treatment success. Taken together, the
results suggest when and why some therapies fail, deter-
mine the efficacy needed for successful treatment, identify
potential immune effects, and show how the regulation of
underlying mechanisms can be used to design new thera-
peutic strategies.
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Introduction
Influenza virus infections result in 15–65 million infec-
tions, over 200,000 hospitalizations, and over 30,000
deaths each year in the U.S. [32, 45]. This is in part due to
the number of antigenically distinct influenza virus strains,
the lack of comprehensive strain coverage in the vaccines,
and the complications arising from underlying health
conditions and/or secondary bacterial infections (SBIs).
SBIs, in particular, have accounted for 40–95 % of
influenza-related mortality in past pandemics
[4, 17, 29, 48]. Vaccines against bacterial pathogens can
reduce the coinfection component [15, 25, 27], but their
efficacy is limited to the vaccine strains and some bacterial
vaccines have reduced effectiveness in influenza virus-in-
fected hosts [25, 27]. Treatment with antimicrobial agents
may also improve disease outcome and reduce SBI inci-
dence [7, 8, 12, 13, 18, 21, 26], but many provide only
partial protection, have time dependent efficacy, and/or
cause adverse effects. Thus, new preventative and thera-
peutic strategies are needed. These may require utilizing
current antimicrobial agents on different time scales and/or
exploiting the mechanisms that regulate disease to increase
the efficacy of treatment or to develop new targets.
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Antivirals for use against the influenza virus slow disease
progression and reduce symptoms by preventing new host
cells from being infected [9]. However, this does not typi-
cally result in a significant reduction in viral burden
[1, 18, 21], and the efficacy is reduced if therapy is initiated
more than 2–3 days after symptom onset [1, 21]. The
decreased efficacy late in infection occurs because the
antivirals target stages in the viral life cycle (i.e., infection
of cells, and virus replication and production) that are
dominant only during the first 2 days post-influenza infec-
tion (pii) [40]. Although the duration and severity of the
viral infection are not reduced with late antiviral treatment,
treatment as late as 5 days pii can slow the progression of
pneumonia and decrease SBI mortality [21]. The mecha-
nism(s) underlying this effect are unclear, but the nominal
reduction in viral loads may have sufficient downstream
consequences on the immune response. Antiviral treatment
may also reduce the post-bacteria viral load rebound that is
observed during some SBIs [39, 43, 47], which may be due
to an increase in virus production/release [43, 46].
Antibiotics directly target the pathogen by causing lysis or
by inhibiting protein synthesis, but these drugs have limited
effects in coinfected hosts [7, 12, 13, 16]. Lytic antibiotics
(e.g., ampicillin) effectively reduce pathogen load during
SBIs, but do so at the expense of a robust inflammatory
response [7, 12]. In contrast, inhibitory antibiotics (e.g.,
clindamycin and azithromycin) have reduced bactericidal
effects but limit tissue damage and inflammation [12, 13, 16].
Although this class of drugs can provide a clinical cure pri-
marily through their anti-inflammatory effects and are bene-
ficial in treating coinfected animals, the high pathogenic
burden is problematic and may lead to drug resistance.
Combining a drug that rapidly eliminates bacteria (e.g.,
ampicillin) with one that has anti-inflammatory effects
(e.g., corticosteroid) seems optimal and does reduce
immunopathology during severe pneumonia; however, pro-
phylactic use of corticosteroids impairs viral clearance [7].
Because traditional therapeutic agents like antivirals and
antibiotics are suboptimal, targeting specific inflammatory
pathways may increase the probability of success. However,
this approach requires knowledge about the underlying
mechanisms of disease. Several factors affect the likelihood
of SBI-associated pneumonia developing, including viral and
bacterial strains, transmitted dose size, timing of bacterial
exposure, and host immune status (reviewed in
[3, 20, 24, 33–35, 37]). In addition, different mechanisms are
likely involved in the various stages of SBIs, e.g., bacterial
invasion, pathogen kinetics, inflammation, and mortality.
Therefore, various therapeutic approaches may be possible.
To help tease apart the contribution of different mechanisms
on bacterial acquisition and pathogen titer trajectories, my
colleagues and I developed a kinetic model [38, 43] that
suggested bacterial invasion is due to the virus removing the
protective effect of alveolar macrophages (AMs) with 85–
90 % efficiency at 7 days pii. Although the underlying
mechanism was thought to be a functional inhibition medi-
ated by interferon-c [28, 44], another study better identified
the kinetics of these cells and found that AMs are depleted
during influenza virus infection [8]. Remarkably, these data
validated our model predictions and the maximum amount of
depletion, which occurs at 7 days pii [8] and corresponds to
the greatest lethality [22], matched our parameter estimate of
85–90 % [43]. Because the AM population is tightly con-
nected to early bacterial clearance, therapeutically replen-
ishing the AM population through immunotherapy during
influenza virus infection can improve the pathogenic burden
and significantly reduce pneumonia [8].
Knowing the model accuracy and the kinetics of AM
depletion allowed us to mathematically derive and exper-
imentally validate a nonlinear relationship between bacte-
rial dose/load and AM depletion that regulates bacterial
invasion and kinetics during the initial stages of infection
[38]. Understanding these dynamics and their regulation
with mathematical precision provides important insight
into the possibility of using therapeutics to alter each
component and the efficacy necessary for the treatment to
be successful. That is, therapeutically reducing the bacte-
rial load (e.g., via antibiotics) will have the same result as
increasing the number of AMs (e.g., via immune modula-
tory drugs or by reducing virus with antivirals), but the
nonlinearity of the relationship indicates differential and
time-dependent therapeutic requirements.
To further understand the viral and bacterial kinetics
under therapy, I used mathematical models [41, 43] and
published data on the dynamics after therapy in BALB/cJ
mice [8, 12, 21] to investigate the efficacy of an antiviral, an
antibiotic, and an immune modulatory agent in the preven-
tion and treatment of influenza and influenza-associated
SBIs. The models were used to predict how pathogen
dynamics would change under each therapy and to quantify
the therapeutic benefit for various intervention efficacies and
timing, the minimum therapeutic requirement to achieve a
clearance or resolution phenotype, and the potential of
combination therapy. The results provide insight into the
failure of current therapies, the time-scale of the greatest
therapeutic benefit, the efficacy of mono-therapy versus
combination therapy, the potential immune consequences of
some drugs, and the possibility of new therapeutic targets.
Methods
Influenza virus infection model
To describe the kinetics of influenza virus infection, a target
cell limitedmodel [2] was used. Themodel tracks populations
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of susceptible epithelial (‘‘target’’) cells (T), newly infected
cells that are not yet producing virus (I1), infected cells that
have undergone an eclipse phase and are producing virus (I2),
and free virus (V). Target cells become infected with virus at
rate bV . Infected cells (I1) first enter an eclipse phase at rate
k then transition to produce virus at rate p. Productive infected
cells (I2) are lost at rate d and virus is cleared at rate c. Equa-
tions (1–4) represent these dynamics and the model parame-
ters are provided in Table 1. The model schematic and fits to
viral titers frommice infectedwith influenzaA/PuertoRico/8/






¼ bTV  kI1 ð2Þ
dI2
dt
¼ kI1  dI2 ð3Þ
dV
dt
¼ pI2  cV ð4Þ
Influenza-pneumococcal coinfection model
To describe the kinetics of influenza-pneumococcal coin-
fection, a model that couples single infection models for
influenza virus (Eqs. (1–4)) [2] and pneumococcus [42]
Table 1 Parameter values of the influenza virus infection model (Eqs. (1–4)) [41], the pneumococcal model (Eq. (9) with V ¼ 0) [42], the
coinfection model (Eqs. (5–9)) [38, 43], and under therapy with antimicrobial agents.
Parameter Description Value Units
Influenza A virus
b Virus infectivity 2.8 106 ðTCID50Þ1 day1
k Eclipse phase 4.0 day-1
d Infected cell death 0.89 day-1
p Virus production 25.1 ðTCID50Þ day1
c Virus clearance 28.4 day-1
T(0) Initial uninfected cells 107 cells
I1ð0Þ Initial infected cells 0 cells
I2ð0Þ Initial infected cells 0 cells
V(0) Initial virus 2.0 TCID50
Pneumococcus
r Bacterial growth rate 27.0 day-1
KP Carrying capacity 2.3 108 CFU
cMA Phagocytosis rate 1.35 104 cell1 day1
n Maximum bacteria per AM 5.0 ðCFUÞcell1
x Nonlinearity in f ðP;MAÞ 2.0
MA Number of AMs 106 cells
P0 Initial bacteria See text CFU
Coinfection
/ Decrease in phagocytosis rate 0.87 (7 days), 0.646 (3 days)
KPV Half-saturation constant 1.8 103 TCID50
a Increase in virion production/release 1:2  103 ðCFUÞz
z Nonlinearity of virion production/release 0.50
w Increase in carrying capacity 1.2 108 ðTCID50Þ1
l Toxic death of infected cells 5.2 1010 ðCFUÞ1
Therapy
ev Efficacy of antiviral treatment See text
et Rate of target cell protection by antivirals 0.68 day
-1
eg Efficacy of rGM-CSF treatment See text
ec Efficacy of clindamycin treatment See text
ea Bacterial death rate from ampicillin treatment 11.35 day
-1
ei Bacterial death rate from additional immune responses
under clindamycin treatment
3.0 day-1
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and includes terms that describe their interactions [43] was
used. In this model, the pneumococcal population (P) is
tracked in addition to the four populations in Eqs. (1–4).
Bacteria replicate logistically with maximum rate r and tis-
sue carrying capacity KP. The model considers the initial
interaction between pneumococci and the first arm of the
immune system, AMs (MA), which phagocytose bacteria at
rate cMAf ðP;MAÞ per cell. This rate decreases as the number
of pneumococci increases according to f ðP;MAÞ ¼ nxMA=
ðPx þ nxMAÞ, where each AM is able to phagocytose a
maximum of n bacteria and x is the shape parameter that
describes the consumption rate of pneumococci. Virus fur-
ther decreases this clearance rate according to /^ðVÞ ¼ /V=
ðKPV þ VÞ. This term drives bacterial invasion [43] and
matches the percentage of AM depletion [8, 38]. Once bac-
teria invade, virus production/release from infected epithe-
lial cells (pI2) is increased by a factor of a^ðPÞ ¼ aPz. This
term drives the viral rebound (Fig. S2) [43], whichmay result
from IFN inhibition as a consequence of bacterial attachment
to infected cells [43, 46]. The model also assumes that virus
infection increases the tissue carrying capacity bywV , which
may facilitate bacterial adhesion to cells, and that bacteria
increase infected cell death by lP. However, these two
effects were shown to have minimal influence on the
dynamics [43]. Altering other processes in the model,
such as the rates of viral infection (bV) and clearance (c),
produced minimal effects on model dynamics. Equa-
tions (5–9) represent these dynamics and the model param-
eters are provided in Table 1. The model schematic and fits
of the model to viral and bacterial titers frommice infected 7







¼ bTV  kI1  lPI1 ð6Þ
dI2
dt
¼ kI1  dI2  lPI2 ð7Þ
dV
dt
¼ pI2 1þ a^ðPÞð Þ  cV ð8Þ
dP
dt
¼ rP 1 P
KP 1þwVð Þ
 
 cMAf ðP;MAÞMAP 1 /^ðVÞ
 
ð9Þ
Model simulations and parameters
MATLAB ordinary differential equation (ODE) solver
(ode45) was used to simulate all equations. The parameter
values used in this study are given in Table 1 or are stated
in the text. The influenza model parameters were obtained
by fitting Eqs. (1–4) to viral titer data from individual mice
infected with 100 TCID50 (50 % tissue culture infectious
dose) PR8 [41]. The pneumococcal model parameters were
obtained by matching Eq. (9) with V ¼ 0 to bacterial titer
data from individual mice infected with 104, 105, or 106
colony forming units (CFU) pneumococcal strain D39 [42].
The coinfection model parameters were obtained by fitting
Eqs. (5–9) to viral and bacterial titer data from individual
mice infected with 100 TCID50 PR8 followed by 1000
CFU D39 at 7 days pii [43]. The coinfection model and
parameters also matched the bacterial titer data from mice
infected with pneumococcal strain A66.1 [43], which is the
strain used in the studies described below.
Initial dose threshold
Equations (5–9) were previously used to derive an initial
dose threshold that describes the relationship between
bacterial dose/load and AM depletion [38]. This threshold
is defined by Eq. (10), which is the unstable steady state
solution (T, I1 , I

2 , V
, P) = (0,0,0,0,P) when /^[ 0. P
satisfies P3 þ BP2 þ CPþ D ¼ 0. This state separates the
two stable steady states (0,0,0,0,0) and (0,0,0,0,KP) and is
constant when virus-induced AM depletion is absent (i.e.,
when /^ ¼ 0) and dynamic when virus-induced AM
depletion is present (i.e., when /^[ 0). The threshold,
shown in Fig. 2b, dictates whether bacteria exhibit a
growth phenotype (to stable state P = KP) or a clearance
phenotype (to stable state P = 0). That is, bacterial loads
decrease for dose-depletion pairings below the threshold
and increase for dose-depletion pairings above the thresh-
old. Additional details can be found in Ref. [38] along with
the experimental validation of these dynamics.
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/^Þ[ 1 (i.e., D[ 0). However, P is complex when




ð1 /^Þ\1 (i.e., D\0). The point where P switches
from being a real root to a complex root with real part less






rcrit ¼ ð1 /^ÞcMAMA ð12Þ
Therapeutic benefit
The area under the curve (AUC) is used to quantify the
benefit of administering a particular drug. To estimate the
therapeutic benefit, the pathogen load was estimated at
discrete time points by the numerical solution to Eqs. (5–9)
or to Eq. (10) and the trapezoidal rule is used to estimate
the AUC.
Data
To investigate infection kinetics under therapy, data from
three published studies were used [8, 12, 21]. These studies
use the same experimental model system that was employed
to parameterize the viral infection model (Eqs. (1–4)) and
the coinfection model (Eqs. (5–9)) [41, 43]. The data from
each study was digitized using PlotDigitizer [31].
Data under antiviral therapy
The viral titer data used to investigate the dynamics under
antiviral therapy was taken from Ref. [21]. In this study,
groups of 6–8 weeks old female BALB/cJ mice (Jackson
Laboratory, Bar Harbor, ME) were lightly anesthetized
with 2.5 % inhaled isoflurane and infected intranasally
with 50 TCID50 PR8 in 100 ul. Mice were then mock-
treated with PBS or given a neuraminidase inhibitor (NAI)
(oseltamivir, 5 mg/kg) twice daily by oral gavage for 5
days beginning 4 h before infection (prophylaxis) or 5 days
pii (late administration). Mice were euthanized by CO2
inhalation at 3 days pii or 7 days pii and the viral titers
were enumerated.
Data under GM-CSF therapy
The bacterial titer used to investigate the dynamics under
GM-CSF therapy was taken from Ref. [8]. In this study,
groups of 6–8 weeks old female BALB/cJ mice (Jackson
Laboratory, Bar Harbor, ME) were given 25 lg recombi-
nant granuloctye macrophage colony stimulating factor
(rGM-CSF) intranasally in 100 ll 1 day before and 1 day
after infection with PR8 at a dose of 25 TCID50 in 100 ul.
Groups of mice were then mock-infected with PBS or
infected with 200 CFU pneumococcus A66.1 at 3 days pii.
For all infections, mice were lightly anesthetized with
2.5 % inhaled isoflurane. After euthanasia by CO2 inhala-
tion at 3 h post-bacterial infection (pbi), bronchoalveolar
lavage fluid (BALF) was collected and the bacterial titers
were enumerated.
Data under antibiotic therapy
The bacterial titer data used to investigate the dynamics
under antibiotic therapy was taken from Ref. [12]. In this
study, groups of 6–8 weeks old female BALB/cJ mice
(Jackson Laboratory, Bar Harbor, ME) were lightly anes-
thetized with 2.5 % inhaled isoflurane and infected with 37
TCID50 PR8 in 100 ll then with 200 CFU pneumococcus
A66.1 in 100 ll at 7 days pii. Bioluminescent imaging was
used to monitor the development of pneumonia. At the
onset of pneumonia, mice were mock-treated with PBS or
treated with ampicillin (100 mg/kg) or clindamycin
(15 mg/kg) administered by intraperitoneal injection twice
daily. The bacterial titers were enumerated by biolumines-
cent imaging in live mice at 0, 12, and 24 h after treatment
initiation. The data are reported as relative light units (RLU)
per minute. To explore these data with a model that has
parameters with units in CFU, a log-log correlation between
CFU and RLU (Fig. S3) is used and defined by Eq. (13).
log10 ðRLUÞ ¼ 0:448 log10 ðCFUÞ þ 2:1068 ð13Þ
Results
Dynamics under antiviral therapy
Antivirals reduce the viral load and, in turn, lessen the
disease severity. This is sufficient to reduce the morbidity
and mortality caused by SBIs [18, 21]. Prophylaxis with
NAIs can reduce viral titers by 2.5–3.0 log10 TCID50 and
SBI mortality by 50 %, whereas late administration (be-
ginning at 5 days pii) results in 0:8 log10 TCID50 lower
viral loads and 33 % less SBI-associated mortality (see
’Methods’ section) [21].
The differential efficacy of early versus late adminis-
tration has been explained by using Eqs. (1–4), where
approximate solutions of the model define the contribution
of each infection process (e.g., virus infection, production,
clearance, etc.) [40]. In brief, the model solution during the
growth phase of the virus (first 2 days pii) indicates that the
processes dominating the kinetics are those that are tar-
geted by antivirals, i.e., VðtÞ ¼ aekt, where k is a combi-
nation of all model parameters. However, the slower rate of
virus growth after this time suggests that the infection
processes are changing and that this is the point where
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antivirals that target the viral life cycle begin to lose their
efficacy. The later stages of infection ([3 days pii) are
dominated by a single process, i.e., infected cell clearance
(VðtÞ ¼ gedt). With a single parameter controlling the rate
of virus load decay, an antiviral that targets this process
may be more efficacious. These dynamics are summarized
in Fig. 1a.
To further illustrate the time-dependent changes in
antiviral efficacy, Eqs. (1–4) were simulated assuming that
NAIs inhibit the rate of virus production (p) with efficacy
ev (i.e., pð1 evÞ). When therapy is initiated at 0d pii
(prophylaxis), setting ev=60 % matches the viral titer data
at 3 days pii but fails to capture the lower titer at 7 days pii
(Fig. 1b). When therapy is initiated at 5 days pii (late
administration), there is little change in the viral titers and
an efficacy of ev=60 % overestimates the decline (Fig. 1d).
Using the same efficacy (ev=60 %) to investigate thera-
peutically targeting other infection processes suggests that
there is little difference between targeting virus production
(p) and infection (b), that increased efficacy is needed for
therapies directed against virus replication (k) or clearance
(c), and that a therapy designed to increase the rate of
infected cell clearance (d) could result in faster clearance
(Fig. 1b–d). Perturbing any of these processes with the
exception of the eclipse phase (k) also resulted in fewer
cells becoming infected if the antiviral is given prophy-
lactically (Fig. 1c). However, there is no effect on target
cells with late administration due to these cells being
depleted by 5 days pii (not shown).
The model in Eqs. (1–4) excludes specific host respon-
ses, which may be altered when virus production (p) is
inhibited by NAIs. Increasing the rate of virus clearance (c)
in addition to the rate of virus production could not
reproduce the data. Increasing the rate of infected cell
clearance (d) could capture the dynamics under NAI pro-
phylaxis but not under late administration (not shown).
Alternatively, innate immune responses (e.g., interferons)
or other host factors may remove target cells (T) from the




¼ bTV  etT; ð14Þ
where et is the rate that these cells become protected.
Including this effect in Eqs. (1–4) in addition to the inhi-
bition of virus production (pð1 evÞ) and setting
ev = 10 % and et = 0.68 d1 can simultaneously repro-
duce the data under NAI therapy at both 0 days pii and 5
days pii (Fig. 1e).
Dynamics under immunotherapy
Because AM depletion drives pneumococcal establishment
during influenza virus infection [8, 38, 43], restoring the
AM population or preventing the depletion reduces bacte-
rial burden [8] and may be able to prevent pneumococcal
invasion altogether. Mice treated with rGM-CSF 1 day
before and 1 day after infection with PR8 (Fig. 2a, see
Fig. 1 Breakdown of viral kinetics and effects of antiviral therapy.
a Fit (black line) of Eqs. (1–4) to viral titers in the lungs of mice
infected with 100 TCID50 PR8 (black squares) [41]. The equations
and time scale that characterize the phases of exponential growth
(shaded in gray), the transition from growth to clearance (shaded in
white), and the exponential decay (shaded in blue) [40] are shown
along with the most effective antiviral target. b–d Simulation of
Eqs. (1–4) against viral load data under NAI therapy given prophy-
lactically (Panels b–c) or at 5 days pii (Panel d) [21] for no therapy
(black line) and for different antiviral targets [virus infection (b, cyan
line), eclipse phase (k, magenta line), virus production (p, blue line),
virus clearance (c, green line), or infected cell clearance (d, orange
line)] with efficacy ev = 60 %. e Simulation of Eqs. (1–4) against
viral load data under NAI therapy given prophylactically (green bars)
or at 5 days pii (black bars) [21] assuming that NAIs inhibit virus
production (pð1 evÞ) with efficacy ev = 10 % and protect target cells
from being infected (Eq. (14)) at rate et = 0.68 day1. The param-
eters values used for all simulations are provided in Table 1 (Color
figure online)
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’Methods’ section) exhibited an average increase of
 20 % in the AM population 2 days after the end of
treatment (at 3 days pii) [8]. This correlated to an average
decrease of  16 % in the bacterial loads within 3 h pbi
with 2 out of 10 mice achieving resolution within 3 h pbi,
and a 60 % reduction in pneumonia.
In the absence of treatment, AMs are depleted by
64.6 ± 13.2 %, on average, at 3 days pii [8]. This corre-
lates to a threshold value (Eq. (10)) of 4:4 2:1  103
CFU [38]. Because the inoculating dose was 200 CFU,
which is well below this threshold value (Fig. 2b), bacteria
clear rapidly and  24 % of the inoculum remains at 3 h
pbi (Fig. 2c) [8]. Using the percentage of AM depletion as
the value of /^, Eqs. (5–9) were simulated across the data
range (/^ ¼ 51:4 77:8 % AM depletion) and found to
capture the empirical measurements accurately (Fig. 2c).
Under rGM-CSF therapy, AM depletion is reduced by
eg ¼ 18:7 15:7 % [8] (i.e., /^ð1 eg), where eg is the
efficacy of rGM-CSF), which moves the position on the
dose-depletion curve to a location further away from the
threshold (Fig. 2b). This suggests that the bacteria will
clear at a faster rate for the same dose [38]. Indeed, only
 8 % of the inoculum remains at 3h pbi compared to
24 % in the absence of treatment. These dynamics are
accurately predicted by Eqs. (5–9) with values of /^
between 33.7 % and 75:5% (Fig. 2c). The additional
clearance potential (the additional area of green in Fig. 2c)
corresponds to a 33 % decrease in the AUC, which is used
to quantify the therapeutic benefit. The reduction in AM
depletion is sufficient to allow for resolution in some mice,
which the model suggests may have occurred as early as 2h
pbi as indicated by the lower green line in Fig. 2c.
Although two mice resolved the infection and presum-
ably had lower levels of AM depletion, the other eight mice
had bacteria remaining at 3 h pbi. These individuals may
have been among the 40 % that progressed to pneumonia
because bacterial growth can be restored if clearance is
incomplete within 3–4 h pbi [38]. Using the numerical
solution to Eqs. (5–9) to find the minimum number of AMs
(1 /^) needed to achieve resolution (log10ðPÞ ¼ 0) by 3 h
pbi indicated that at least 51 % of the AM population is
required to clear a dose of 200 CFU (Fig. 3a). This cor-
responds to an efficacy of eg ¼ 24 % (i.e., /^ ¼ 64:6
! 49 %) (Fig. 3b). Interestingly, the critical number of
AMs needed to resolve the infection is conserved across
coinfection timings (3 vs 7 days pii) (Fig. 3a), but the
percentage of AM replenishment required is larger at 7
days pii because the baseline value of AM depletion is
greater at this time (/^ ¼ 87 %) than at 3 days pii
(/^ ¼ 64:6 %) (Fig. 3b). This can also be seen by simu-
lating the coinfection model (Eqs. (5–9)) for other per-
centage increases in the AM population (Fig. 3c, d).
Calculating the therapeutic benefit (AUC) for various
increases in the AM population for a coinfection at 3 days
pii or 7 days pii suggests that the greatest benefit occurs
when AM depletion is high (large /^, more severe infection)
and, thus, later in the infection (7 vs 3 days pii) (Fig. 3e).
Similarly, the therapeutic benefit is greater if the infection
is more severe as a result of a high inoculating dose
(Fig. 3f). The more robust response to therapy is due to the
greater slope of the threshold with large /^ (high degree of
AM depletion), as illustrated in Fig. 3g.
Dynamics under antibiotic therapy
The bacterial burden, which can be reduced directly by
antibiotics, contributes to pathogenicity of SBIs during
influenza virus infections. Treating coinfected mice with a
cell wall active agent (ampicillin) or a protein synthesis
inhibitor (clindamycin) at the onset of pneumonia (see
’Methods’ section) showed that ampicillin could reduce
bacterial titers considerably, whereas clindamycin had a
limited ability to reduce titers but lessened the disease
severity by reducing inflammation [12]. This correlated to a
50 % increase in survival in the ampicillin treated mice and
Fig. 2 Effect of rGM-CSF therapy. a Therapeutic schedule used to
evaluate rGM-CSF therapy in mice infected with PR8 (‘‘Flu’’)
followed by 200 CFU A66.1 (‘‘Spn’’) [8]. b Simulation of Eq. (10)
with the parameters in Table 1 and various values of /^. Dose-AM
depletion pairing and distance from the threshold are illustrated for no
therapy (black) and rGM-CSF therapy (green). c Simulation of
Eqs. (5–9) against bacterial load data under no therapy (black) or
rGM-CSF therapy (green). The parameters used are those in Table 1
with the indicated range of AM depletion (/^) (Color figure online)
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an 80 % increase in survival in the clindamycin treated
mice.
To examine the effect of antibiotics on coinfection
kinetics, I assume that pneumococci are killed at rate ea d1
by ampicillin, which directly lyses bacteria, and that the
replication rate (r) is reduced with efficacy ec by clin-
damycin, which inhibits replication. Adding these effects
to Eq. (9) yields
dP
dt
¼ ð1 ecÞrP 1 P
KP
 
 cMAf ðP;MAÞPMAð1 /^ðVÞÞ
 eaP: ð15Þ
To match the model output to the data, it was first neces-
sary to estimate the time at which therapy was initiated
because the authors of the study reported only that therapy
began at the onset of pneumonia as visualized by biolu-
minescent imaging. A reasonable value for the start time
was obtained by simulating Eqs. (5–9) in the absence of
antibiotics (ea ¼ 0, ec ¼ 0) until the numerical solution
[adjusted to RLU with Eq. (13)] matched the first data
point. This resulted in a start time for mock treated mice of
10 h pbi, with the respective start times for the clindamycin
and ampicillin treated mice being 48 min and 91 min later.
With six mice per group, these times correlate to a process
time of 7–8 min per mouse, which is a reasonable length of
time to identify the onset of pneumonia through biolumi-
nescent imaging and administer treatment.
Simulating Eq. (15) together with Eqs. (5–8) beginning
at the times indicated above suggests that the mock treated
mice may have also had altered bacterial kinetics (Fig. 4a).
For the mock treated group (ea ¼ 0, ec ¼ 0), the model
could reproduce the data if the replication rate (r) was
reduced to 6.5 d1. When this value was used to simulate
antibiotic treatment, ampicillin could eliminate bacteria at
a rate of ea ¼ 11:35 d1.
For clindamycin therapy, setting ec ¼ 1 (i.e., 100 %
efficacy) inhibited growth but did not result in decreased
bacterial loads (not shown). Incorporating additional
clearance at a rate of ei ¼ 3 d1 [i.e., replacing ea with ei in
Eq. (15)] could produce the decline seen in the data during
the first 12 h after therapy. However, the data at 24 h
post-treatment showed a rebound in the bacterial titers,
and, thus, the model deviates from the data after 12 h
post-treatment when antibiotic effects are included (not
Fig. 3 Differential therapeutic benefit of decreasing AM depletion.
a Minimum percentage of AMs (1 /^) needed to achieve resolution
(P ¼ 0 log10 CFU) by 3 h pbi for coinfections at 3 days pii (black) or
7 days pii (blue) and for bacterial doses of 200 CFU, 1000 CFU, or
5000 CFU. b Percent efficacy (eg) needed to achieve resolution by 3 h
pbi for a coinfection at 3 days pii or 7 days pii and for a bacterial dose
of 200 CFU (black), 1000 CFU (cyan), or 5000 CFU (magenta). c–
d Simulation of Eqs. (5–9) for different percentage increases in AMs
calculated from baseline for a coinfection at 3 days pii (Panel c) or 7
days pii (Panel d). e–f Calculated therapeutic benefit (change in
AUC) for different percentage increases in the AM population (/^)
(Panel e) or for different dose increases (Panel f) for a coinfection at
3 days pii (squares) or 7 days pii (circles). Green indicates a positive
therapeutic benefit and red indicates a negative therapeutic benefit
(Panel e). g Schematic showing how the slope of the threshold and,
thus, the therapeutic benefit increases more rapidly for higher degrees
of AM depletion. Baseline values of AM depletion at 3 days pii
(square) and 7 days pii (circle) are shown for a dose of 200 CFU.
Unless otherwise noted, the numerical solution to Eqs. (5–9) with the
parameters in Table 1 was used. Baseline is /^ ¼ 64:6 % for a
coinfection at 3 days pii and /^ ¼ 87 % for a coinfection at 7 days pii
(Color figure online)
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shown). Removing the entire effect of antibiotics and the
additional immune-mediated clearance (i.e., setting
ec;i ¼ 0) at 12 h post-treatment could restore the model
accuracy for later time points. The growth in bacterial titers
at this point occurs at the same rate as in the mock treated
mice, suggesting a complete loss of efficacy of the
antibiotic.
While clindamycin works to eliminate bacteria through
non-lytic mechanisms, other antimicrobial agents that tar-
get pathogen replication could also be efficacious. In
addition, earlier administration of the drug should be
beneficial. To quantify how much a drug would need to
reduce the growth rate in order to be effective, Eqs. (5–8)
and (15) were simulated for various values of ec assuming
that therapy begins at 0d pbi (prophylaxis) or at 5 h pbi
(delayed). The model solution indicated that prophylactic
administration would require increasing the doubling time
from 37 min to 56 min (ec ¼ 33:7%) to enable AMs to
control the infection and achieve an immediate clearance
phenotype (Fig. 4b). Delaying treatment to 5 h increased
this doubling time to 61.5 min (ec ¼ 40%; Fig. 4c). If
treatment is delayed even further, the minimum efficacy
required to result in a clearance phenotype increases
rapidly and 100 % efficacy is required at 10 h pbi (Fig. 4d),
which is consistent with the results above that indicated the
efficacy (ec) of clindamycin therapy initiated after 10 h pbi
was 100 %.
The nonlinearity of the required efficacy in Fig. 4d and
the dynamics in Fig. 4b–c illustrate that the replication rate
(r) is a bifurcation parameter, similar to the AM depletion
parameter (/^). That is, differential dynamics occur
depending on the value of r. Indeed, the threshold solution
(Eq. (10)) is dependent on two parameters other than /^, the
rates of bacterial replication (r) and clearance (cMA) (see
’Methods’ section) [38]. Because cMA would be difficult to
therapeutically manipulate, the remaining analyses focus on
r. Plotting the solution to Eq. (10) for various values of
r while keeping all other parameters fixed to the values in
Table 1 illustrates the response to inhibiting the growth rate
(Fig. 4e). That is, the increasing area under the threshold for
decreasing values of r indicates a greater opportunity for
bacterial clearance. The critical value (Eq. (12)) where
clearance potential is gained is rcrit ¼ 0:74 h1, which cor-
responds to a doubling time of 56.2 min.
Potential for combination therapy
Thus far, I have examined how different therapeutic
approaches can alter two different parameters of the coin-
fectionmodel that drive the dynamics [i.e., the degree of AM
depletion (/^) and the bacterial growth rate (r)]. Because the
coinfection dynamics are sensitive to changes in both
parameters, it is possible that they can be altered
Fig. 4 Effect of antibiotic therapy and potential for combination
therapy. a Simulation of Eqs. (5–8) and (15) against bacterial load
data (obtained by bioluminescent imaging, RLU) under mock therapy
(magenta) or antibiotics [ampicillin (green) or clindamycin (cyan)]
[12]. The parameters used are those in Table 1 with ea;c;i ¼ 0 (for no
therapy and mock therapy), r = 6.5 d-1 (for mock (PBS) and
antibiotic therapy), ea ¼ 11:35 d1 (for ampicillin), and ec ¼ 1 and
ei ¼ 3 d1 until  8 days pii and ec;i ¼ 0 thereafter (for clindamycin).
The model output was adjusted to RLU with Eq. (13). b–c Simulation
of Eqs. (5–8) and (15) for various values of antibiotic efficacy (ec) for
prophylactic treatment (beginning at 0d pbi, Panel b) or delayed
treatment (beginning at 5 h pbi, Panel b). d Minimum efficacy (ec)
needed to achieve a clearance phenotype found by simulating
Eqs. (5–8) and (15) for treatment beginning at various times pbi. e–
f Simulation of the threshold solution (Eq. (10)) with various values
of the bacterial growth rate (r) alone (Panel e) or in addition to the
degree of AM depletion (/^) (Panel f) (Color figure online)
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simultaneously through combination therapy with, for
example, an antibiotic (e.g, clindamycin) and immunother-
apy (e.g., rGM-CSF) or an antiviral (e.g., NAI), if reducing
the viral load also reduces AM loss. Plotting the threshold
solution (Eq. (10)) for different values of /^ and r shows how
the threshold increases as the rate of bacterial replication is
reduced (i.e., increasing the efficacy, ec; Fig. 4f). The larger
distance below the threshold, which correlates to the rate of
bacterial clearance, with increasing antibiotic efficacy (ec)
suggests a significant gain in clearance potential with com-
bination therapy. If the AUC of the threshold is used as a
measure of therapeutic potential, an antibiotic efficacy of
40 %, 60 % or 80 % increases the chances of successful
treatment with immunotherapy and/or antivirals by 49 %,
95 %, or 194 %, respectively.
Discussion
Given the severity of influenza virus infections and
influenza-associated secondary bacterial infections, effec-
tively preventing both infections is crucial. The limited
protection and availability of vaccines, together with the
inadequacies of antimicrobial agents, make treating SBIs
challenging. Although suboptimal efficacy may be
unavoidable to some extent, a detailed understanding of
how infection processes change over time and the feedbacks
between various pathogen and host factors aids our ability
to develop new therapeutic strategies and/or targets that
effectively abrogate influenza infections and SBIs.
By utilizing kinetic models describing influenza virus
infection [2, 41] and bacterial coinfection [43] and
exploiting the tight correlation between two factors (i.e.,
bacterial dose/load and AM depletion) that regulate bac-
terial acquisition and initial bacterial titer trajectories
[8, 38, 43], the analysis here shows how infection kinetics
change when different processes are perturbed with
antimicrobial agents. Given that virus infection! AM loss
! reduced bacterial clearance ! increased viral load,
therapeutically targeting these processes should have sim-
ilar effects (Fig. 5). However, the nonlinearity of the
relationship between AM depletion, the bacterial load/-
dose, and the bacterial growth rate (Figs. 4f, 5) illustrates
that the extent to which pathogen loads can be therapeu-
tically reduced is dependent on the time of administration
(i.e., location on the threshold axes) and the mechanism of
action of the drug (Figs. 3, 4, 5). In addition, the steeper
slope of the threshold for high values of AM depletion
(Fig. 3g) highlights the faster response to therapies that
decrease the depletion when the infection is more severe,
but this is complicated by a greater therapeutic efficacy
needed to resolve the infection (Fig. 3). The response to
therapy will be increased further when bacterial growth is
also inhibited (i.e., during combination therapy) because
Fig. 5 Summary of therapeutic strategies to combat SBIs during
influenza. Schematic of the regulating mechanism driving SBIs
during influenza virus infections and various therapeutic strategies
targeted at each process. Influenza virus infection results in the
depletion of alveolar macrophages (AMs), which in turn allows for
bacteria to invade and grow. This bacterial growth then increases the
viral load. Antiviral therapy (AV) can reduce virus growth, which
may in turn decrease AM depletion. AM depletion can be reduced by
immunotherapy (IM), which improves bacterial clearance. Antibiotics
(Abx) can reduce the bacterial loads and/or the bacterial growth rate,
which may reduce the post-bacterial viral load rebound. The figure in
the center shows the relationship between AM depletion (x-axis),
bacteria load (y-axis), and bacterial growth rate (colored lines), as
defined by Eq. (10). Values above/below the threshold lines support
growth/clearance phenotypes. Also depicted are the ways in which
each therapy can be used alone or in combination (i.e., by using Abx
to slow bacterial growth (from the black line to the blue line) or to
reduce bacterial loads, and by using IM or AV to reduce AM loss)
(Color figure online)
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the slope of the threshold is steeper (Fig. 4f). The addi-
tional area under the threshold with combination therapy
also suggests that it may be possible to decrease the amount
of drug used and/or the length of therapy. In contrast,
manipulating only the growth rate would require a higher
efficacy than manipulating the AM population because of
the slower rate of change of the curve in Fig. 4e.
Although the mechanism resulting in AM loss during
influenza is unknown, viral loads may be directly related
to AM depletion [38]. Data obtained by manipulating the
dose-depletion combination suggested that when bacterial
loads decline in the first 4 h pbi (i.e., dose-depletion
pairing below the threshold), but do not clear, bacteria can
overcome AMs and switch to a growth phenotype [38].
When this occurs, it results in a large degree of hetero-
geneity in bacterial loads at 24 h pbi, whereas little
heterogeneity results from dose-depletion pairings above
the threshold [38]. This observation provided insight into
the coinfection dynamics with the PR8-PB1-F2(1918)
virus, for which bacterial titers diverged by 24 h pbi [43].
In these mice, viral titers were also lower at the onset of
the coinfection [41, 43], which suggested a dose-depletion
pairing below the threshold. Although it is unknown if
there was less AM depletion with this virus, the correla-
tion led to the hypothesis that viral titers are linked to the
depletion of these cells. This may help explain why even
small reductions in the viral load as a result of antiviral
treatment can lead to substantial reductions in SBI mor-
bidity and mortality [21]. It is also possible that reducing
viral loads with antiviral treatment has additional effects
on host immune responses or other host factors (e.g., as in
Fig. 1e) that are beneficial in decreasing the incidence and
pathogenicity of SBIs. With several anti-influenza drugs
not yet licensed for use in the U.S. or under development
(reviewed in [11]), it will be important to test their effect
on immune components and their efficacy in animal
coinfection models.
Treatment with antiviral agents may prevent the detri-
mental effects on AMs during influenza virus infection, but
the cell population can also be restored by immunotherapy
with agents like rGM-CSF [8]. Even with a short treatment
regimen that resulted in  20 % efficacy, bacterial clear-
ance for a low dose infection could be improved, gener-
ating a 33 % therapeutic benefit. However, the results
presented here suggest that more severe infections, such as
those initiated by larger doses, would require significantly
greater efficacy (Fig. 3a, b). It is unclear if another treat-
ment schedule with rGM-CSF or an alternate drug could
improve these figures. Because rGM-CSF therapy has some
drawbacks, such as increasing inflammation (reviewed in
[10]), that may inhibit its use during influenza-associated
diseases, developing other therapies that increase the AM
population is necessary.
Reducing the pathogen load is the goal of many thera-
peutics, including antivirals and antibiotics, but the
pathogen titers do not always correlate with disease. Fur-
ther, reducing inflammation directly or through reduction
of the pathogen burden often leads to a better outcome.
Protein synthesis inhibitors (e.g., clindamycin), which slow
bacterial replication in addition to having anti-inflamma-
tory effects [12, 13], are one example of such a treatment.
However, decreasing the inflammatory response leads to a
rebound in bacterial loads [12] (Fig. 4a), which has been
attributed to a lower neutrophil influx into the lungs
mediated by Toll-like receptor 2 (TLR-2) [13]. This may
explain why it was necessary to remove the effect of
antibiotics (ec) and the additional immune response (ei) in
Eq. (15) shortly after therapy initiation in order to match
the data (Fig. 4a). Although neutrophil dynamics are cur-
rently excluded from the model, ei reflects bacterial
phagocytosis by these cells. An understanding of the rela-
tive effects of neutrophils on pathogen kinetics and
inflammation/disease may aid the design of new thera-
peutic approaches, particularly given that these cells
undergo influenza-induced apoptosis and become dys-
functional during SBIs [5, 6, 14, 23, 30, 36] and that TLR-2
antagonists can protect against SBIs [26].
Kinetic models provide a robust means of evaluating
how infection kinetics change when different processes are
perturbed by therapeutics. These models yield important
information about the feasibility of attaining a particular
outcome (e.g., clearance within a distinct time frame), the
off-target effects of a drug (e.g., on immune responses),
and the time-scale on which a drug is most effective. In
addition, establishing how different mechanisms are related
pinpoints strategies that can simultaneously alter each
pathway and provides insight into the impact of using
multiple therapies. Determining how other pathogen and
host factors work together will undoubtedly identify new
therapies for these diseases.
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